Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Immune cells linked to insulin resistance in new study

NCT ID NCT05329337

Knowledge-focused Sponsor: Centre Hospitalier Universitaire de Nīmes Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether immune cells from healthy people can affect how the body responds to insulin. Researchers took blood samples from 30 volunteers and tested how their immune cells influenced insulin signaling in liver cells in the lab. The goal was to better understand the connection between the immune system and conditions like insulin resistance and high insulin levels.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could help explain how the immune system contributes to insulin resistance, potentially pointing toward new ways to prevent or manage type 2 diabetes.
What could go wrong
This is a very small, early-stage observational study with only 30 participants. It is designed to gather information, not to test a treatment, so it may not lead to any direct medical advances.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

30 people

The number who actually took part.

Started

Jun 2022

Finished

Oct 2023

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Individuals who participated in the MetACTIV study. * Profile 2 subgroup-specific inclusion criteria: * MetACTIV study individual with a Profile 2. * Persons who have given free informed consent. * Persons who have signed the consent form. * Persons affiliated to or benefiting from a health insurance plan. * Adults (≥18 years of age). Exclusion Criteria: * Persons participating in Category 1 research involving human subjects * Persons in an exclusion period as determined by another study. * Persons under court protection, guardianship or trusteeship. * Persons who are incapable of giving consent. * Persons for whom it is impossible to give clear information. * Pregnant, parturient or breastfeeding woman.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hyperinsulinism are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

hyperinsulinism immune system disorder Insulin Resistance

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hyperinsulinism Immune system Insulin resistance

Contacts and locations

Locations

  • Caisse Primaire d'Assurance Maladie du Gard

    Nîmes, Gard, 3000, France

  • Centre Hospitalier Universitaire

    Nîmes, Gard, 30000, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.